Kornimate/medical-research-clean huggingface dataset:
myocardial infarction, combined-device, recovery enhancement study

Conditions: Acute Myocardial Infarction; Coronary Artery Disease; Acute Coronary Syndrome; Myocardial Infarction

Summary: unplanned readmissions after hospitalization for acute myocardial infarction (ami) are among the leading causes of preventable morbidity, mortality, and healthcare costs. digital health interventions (dhi) could be an effective tool in promoting self-management, adherence to guideline directed therapy, and cardiovascular risk reduction. a dhi developed at johns hopkins-the corrie health digital platform-includes the first cardiology apple carekit smartphone application, paired with an apple watch and ihealth bluetooth-enabled blood pressure monitor. corrie targets: (1) self-management of cardiac medications, (2) self-tracking of vital signs, (3) education about cardiovascular disease through articles and animated videos, and (4) care coordination that includes cardiac rehabilitation and outpatient follow-up appointments. in this prospective study, stemi or type 1 nstemi patients are being enrolled to use the corrie health digital platform beginning early during participants' hospital stay. enrollment sites include johns hopkins hospital, johns hopkins bayview medical center, massachusetts general hospital, and reading hospital. the primary objective is to compare time to first readmission within 30 days post-discharge among patients with the corrie health digital platform to patients in the historical standard of care comparison group.


Eligibility criteria:
corrie health digital platform group inclusion criteria: * admitted for acute myocardial infarction (stemi or type 1 nstemi) * 18 years or older * english-speaking * own any type of smartphone exclusion criteria: * visual, hearing, or motor impairment which precludes the use of the intervention * inability to participate due to severity of illness (e.g., intubated and on sedation in the setting of cardiogenic shock). if patients are deemed clinically unstable and unable to participate at the time of initial screening, the research team member returns at a later date to determine whether this status has changed. historical standard of care comparison group inclusion criteria: * admitted for acute myocardial infarction (stemi or nstemi) * 18 years or older * english-speaking exclusion criteria: * none

Keywords: readmission cardiovascular disease prevention cardiovascular disease risk factors cost-effectiveness heart attack acute myocardial infarction secondary prevention digital health smartphone app self-management guideline adherence behavior modification
a study to assess the efficacy and safety of bivv009 (sutimlimab) in participants with primary cold agglutinin disease who have a recent history of blood transfusion (cardinal study)

Conditions: Agglutinin Disease, Cold

Summary: the purpose of part a was to determine whether sutimlimab administration resulted in a greater than or equal to (\>=) 2 grams per deciliter (g/dl) increase in hemoglobin (hgb) levels or increased hgb to \>= 12 g/dl and obviated the need for blood transfusion during treatment in participants with primary cold agglutinin disease (cad) who had a recent history of blood transfusion. the purpose of part b was to evaluate the long-term safety and tolerability of sutimlimab in participants with cad.


Eligibility criteria:
inclusion criteria: * body weight of \>= 39 kg at screening. * confirmed diagnosis of primary cad based on the following criteria: a) chronic hemolysis; b) polyspecific direct antiglobulin test (dat) positive; c) monospecific dat strongly positive for c3d; d) cold agglutinin titer \>= 64 at 4 degree celsius; e) immunoglobulin g (igg) dat less than or equal to (\<=) 1+, and f) no overt malignant disease. * history of at least one documented blood transfusion within 6 months of enrollment. * hemoglobin level \<= 10.0 g/dl. * bilirubin level above the normal reference range, including participants with gilbert's syndrome. exclusion criteria: * cold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy. * clinically relevant infection of any kind within the month preceding enrollment (e.g., active hepatitis c, pneumonia). * clinical diagnosis of systemic lupus erythematosus; or other autoimmune disorders with anti-nuclear antibodies at screening. anti-nuclear antibodies of long-standing duration without associated clinical symptoms adjudicated on a case-by-case basis during the confirmatory review of patient eligibility. * positive hepatitis panel (including hepatitis b surface antigen and/or hepatitis c virus antibody) prior to or at screening. * positive human immunodeficiency virus (hiv) antibody at screening. * treatment with rituximab monotherapy within 3 months or rituximab combination therapies (e.g., with bendamustine, fludarabine, ibrutinib, or cytotoxic drugs) within 6 months prior to enrollment.
hürthle cell carcinoma and follicular thyroid carcinoma

Conditions: Huerthle Cell Carcinoma

Summary: the goal of this retrospective study is to evaluate in patients with hcc and ftc who underwent lobectomy. the main questions it aims to answer are: * the necessity of completion thyroidectomy based on the clinicopathological characteristics * prognosis participants underwent thyroid lobectomy researchers compared hcc and ftc groups to see the prognosis after lobectomy.

background the prognosis of hürthle cell carcinoma (hcc) and follicular thyroid carcinoma (ftc) is poorly understood. these types of cancers are usually confirmed after diagnostic lobectomy. we aimed to evaluate the clinicopathological characteristics and prognoses of patients with hcc and ftc who did not undergo completion thyroidectomy. materials and methods we screened 221 patients diagnosed with ftc or hcc after thyroid lobectomy at yonsei severance hospital between january 2000 and december 2020. after excluding patients who underwent complete thyroidectomy, 184 patients with ftc and 37 patients with hcc were included.

Eligibility criteria:
inclusion criteria: * follicular thyroid carcinoma * hurthle cell carcinoma * lobectomy exclusion criteria: * completion thyroidectomy * total thyroidectomy
omic approaches to neurodevelopmental disabilities

Conditions: Neurodevelopmental Disorders

Summary: to bridge the gap between the molecular structure of cnv and the effect on the phenotype, considering ndds as complex diseases, as they are a consequence of the imbalance in several dosage-sensitive genes, we might try to approach them through different --omics investigations (genomics, epigenomics, transcriptomics) according to the emerging field of network medicine. this holistic can provide valuable insight into understanding peculiar molecular mechanisms and unsuspected molecular interactions that contribute to the pathogenesis of the condition and possibly pave the way for uncovering new drug strategies that even if they do not heal the patient may improve his performance and the social interaction


Eligibility criteria:
inclusion criteria: patients with neurodevelopmental disorders carrying a genomic rearrangement identified through chromosomal microarray analysis (cma) exclusion criteria: na

Keywords: whole genome sequencing transcriptome analysis genotype phenotype structural variants
effect of fructose reduction on non-alcoholic fatty liver disease (nafld) and metabolic syndrome in overweight children

Conditions: Non-alcoholic Fatty Liver Disease

Summary: the aim of the present study is to find out if a dietary intervention mainly focusing on fructose reduction has a preventive effect on the development and progression of nafld and the metabolic syndrome in overweight children.

in the intervention study a total of 100 overweight and 50 normal weight children, aged 5-8 years have to be included. at the beginning, two 24-h dietary recalls are performed to assess nutritional intake and fructose consumption. anthropometric parameters (body weight and height) are measured to calculate bmi and bmi-sds of the children. physical activity during leisure time as well as socio-demographic status and "family background" are assessed using different questionnaires. an ultrasound examination of the liver is performed in all participants for detection of signs of fatty liver. from each child included in the study a fasting blood sample is taken to determine the following blood parameters: alt, ast, γ-gt, uric acid, blood lipids (tg, hdl, ldl, total cholesterol), blood alcohol, pai-1 and endotoxin concentration. a part of the blood sample is used for dna-analysis. in all children systolic (sbp) and diastolic (dbp) blood pressure are also measured. an oral glucose tolerance test (ogtt) is performed after an overnight fast of 12 h (glucose concentration: 1.75 g/kg body weight, maximum 75g). simultaneously a glucose hydrogen breath test is performed to assess small intestinal bacterial overgrowth (sibo). after the check-ups at the beginning of the study, children are divided into two study groups: the intervention group and the control group. based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. in the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained. if families participating in the control group wish, they receive a dietary counseling based on the references of the "dge" at the beginning of the study. after the first and the second study year the examinations are repeated in all participants (ultrasound examination only after the second study year).

Eligibility criteria:
inclusion criteria: * bmi \> 90 percentile for overweight children * bmi \< 90 percentile for normal weight children * no signs of fatty liver (maximal fatty liver grade one or slightly elevated alt, ast, γ-gt concentrations) * children with metabolic disorders (prehypertension, high triglyceride, cholesterol or fasting glucose levels) are included with agreement of the pediatrics exclusion criteria: * liver disease (e.g. steatohepatitis) * diabetes type 1 and 2 * renal insufficiency * chronic disease of the gastrointestinal tract * taking drugs affecting lipid or glucose metabolism

Keywords: nafld metabolic syndrome children fructose
non-interventional study of zoladex in endometriosis

Conditions: Endometriosis

Summary: this is a prospective, open label nis, which is to assess the efficacy of zoladex in adjuvant setting after operation in moderate to severe endometriosis patients.


Eligibility criteria:
inclusion criteria: * advanced endometriosis confirmed histologically (r-afs score iii-iv) with conservative laparoscopy or laparotomy. * patient who has the indication of zoladex and has been prescribed zoladex according to physician's judgement, irrespective of the inclusion in the study. * patient has been already prescribed zoladex within 1 month after operation. exclusion criteria: * have used hormone treatment prior to 3 months of recruitment. * involvement in the planning and conduct of the study (applies to both astrazeneca staff or staff at the study site). * previous enrolment in the present study.
chronic presence of epstein barr virus in epithelial cells from gingiva is associated with periodontitis

Conditions: Chronic Periodontitis; Aggressive Periodontitis; Presence / Absence of EBV

Summary: the etiopathogenesis of periodontal disease results from complex interaction between infectious agents, mainly including bacteria, and host cellular and humoral immune responses. however it is thought that bacteria-induced pathogenesis is not sufficient alone to explain all biological and clinical features of the destructive periodontal disease. the main hypothesis is that herpesviruses, such as epstein-barr virus, may participate as well by altering epithelial gingival cell biology and consequently may promote the initiation and progression of periodontitis.


Eligibility criteria:
inclusion criteria: * 10 patients affected by chronic periodontitis * 10 patients affected by aggressive periodontitis * 10 healthy patients (orthodontics extraction) * subject who have read and understood the information note relative under investigation and who have signed the informed consent * major patient exclusion criteria: * patient with no contre-indication to periodontal treatment * patient with serious blood disease * patient who exhibits systemic condition incompatible with realization of the study * patient treated with oral retinoids, bisphosphonates, oral anticoagulants and anticonvulsivants * patient who presents a buccal carcinoma treated with radiotherapy * patient who have received during the past 6 months: anti-inflammatory drugs, anti-cancerous or immunosuppressive chemiotherapy * patient who presents a linguistic or psychic incapacity to understand information
chlorhexidine gluconate versus saline for flushing the surgical area during colorectal cancer surgery

Conditions: Colorectal Cancer; Surgical Site Infection; Chlorhexidine; Complications

Summary: the aim of this study was to compare the effectiveness of chlorhexidine versus saline in flushing the surgical area during colorectal cancer surgery. the primary outcomes included surgical site infection, postoperative complication rates, et al.


Eligibility criteria:
inclusion criteria: 1. patients aged 18-85 years, 2. patients with surgically resectable colorectal tumors confirmed by ct/mri before surgery 3. all patients had a performance status score of 0 or 1 in the eastern tumor cooperative group 4. american society of anesthesiology grade i-iii exclusion criteria: 1. the tumor may have distant metastasis 2. history of previous abdominal surgery 3. the patient has a history of other malignant tumors diagnosed in the past 5 years and has received radiotherapy and chemotherapy in the past 4. there are obvious contraindications to surgery (obvious abnormal liver and kidney function, pregnancy) 5. participated in other clinical trials within the past 6 months
proximal row carpectomy versus four corner fusion

Conditions: Wrist Osteoarthritis

Summary: there are two types of interventions to treat a post-traumatic wrist osteoarthritis: the proximal row carpectomy and the four corner fusion. they are used to reduce pain and to maintain the mobility. in previous studies are shown that the proximal row carpectomy shows a better mobility of the wrist postoperatively, whereas the four corner fusion has lower progression of radiocarpale osteoarthritis. the purpose of this study is to compare the clinical, radiological and subjective outcomes after the treatment with a proximal row carpectomy or a four corner fusion.

two surgical procedures are used to treat a post-traumatic wrist osteoarthritis, especially after scaphoid non-union advanced collapse (snac) and scapholunate advanced collapse (slac): the proximal row carpectomy and the four corner fusion. both surgical procedures are rescue operations. they are used to reduce pain and to maintain the mobility, compared to a complete stiffening of the wrist. in previous studies are shown that the proximal row carpectomy shows a better mobility of the wrist postoperatively and a lower complication rate, whereas the four corner fusion has a lower progression of radiocarpale osteoarthritis and a better grip strength. the purpose of this study is to compare the clinical, radiological and subjective outcomes after the treatment with a proximal row carpectomy or a four corner fusion.

Eligibility criteria:
inclusion criteria: * post-traumatic wrist osteoarthritis * treated with a proximal row carpectomy or four corner fusion * signed written informed consent exclusion criteria: * no knowledge of german
a study to assess benign joint hypermobility syndrome in children with a history of wheezing or asthma

Conditions: Benign Joint Hypermobility Syndrome; Wheezing; Asthma

Summary: the purpose of this study is to assess benign joint hypermobility syndrome (bjhs) in children with a history of wheezing or asthma. bjhs is a common syndrome of joint and connective tissue laxity without any other rheumatologic disease. this assessment will be performed by using either method below depending upon if the child has a history of wheezing or severe asthma: 1. determine the correlation, if there is an increased rate of bjhs in children with a history of wheezing as well as if there is an increased history of wheezing in children with bjhs; or 2. determine asthma control, lung function and asthma exacerbations (a flare up or acute worsening of symptoms) in children with bjhs compared to children with asthma without bjhs, to assess if it bjhs is associated more with children with severe asthma.


Eligibility criteria:
inclusion criteria: * all children ages 6-16 with a history of wheezing or asthma exclusion criteria: * for subjects with a history of wheezing: history of chronic lung disease or prematurity, chronic aspiration, congenital anomalies of the upper and lower airway, primary ciliary dyskinesia, cystic fibrosis, history of heart failure, immune deficiency, or any inflammatory arthritis. * for subjects with a history of asthma: current acute respiratory exacerbation, history of chronic lung disease of prematurity, chronic aspiration, congenital anomalies of the upper or lower airway, primary ciliary dyskinesia, cystic fibrosis, restrictive lung disease, history of heart failure, immune deficiency, or inflammatory arthritis.
a clinical study of kw-3357 in patients with dic

Conditions: Disseminated Intravascular Coagulation (DIC)

Summary: to evaluate the efficacy and safety of kw-3357 with concomitant use of heparin using multi-center, non-comparative, open-label method in patients diagnosed as disseminated intravascular coagulation (dic) by the diagnostic criteria for dic established by the japanese ministry of health and welfare.


Eligibility criteria:
inclusion criteria: * diagnosed or suspected as dic by the diagnostic criteria for dic established by the japanese ministry of health and welfare * antithrombin activity \<= 70% * written informed consent from patient or guardian exclusion criteria: * anamnesis or complication of serious drug allergy * serious liver disorder, such as fulminant hepatitis and decompensated cirrhosis * pregnant, nursing, or possibly pregnant woman * possibility for the promotion of bleeding by concomitant use of heparin
cardiac operation under totally endoscope and cardiopulmonary bypass (cpb)

Conditions: Congenital Heart Defects; Heart Valve Diseases

Summary: conventional cardiac operations are performed with median sternotomy, which is related to great wound, morbidities, longer duration in hospital and most significantly, cosmetic problems. the investigators invested a new minimally invasive cardiac operation method totally under video-endoscope and peripheral cardiopulmonary bypass. the investigators' hypothesis is that this new minimally method could provide better cosmetic effects to the patients, and also relate to shorter postoperative hospital stay and better recovery.


Eligibility criteria:
inclusion criteria: * congenital heart defects or heart valve diseases require surgical correction exclusion criteria: * body weight \< 10kg * committed with complex congenital heart defect * anticipated to perform aortic valve repair or replacement * anticipated to perform aorta repair or replacement * committed with femoral vessel diseases unable to perform femoral cannulation * refuse to perform totally thoracoscope minimally invasive surgery

Keywords: surgical procedures, cardiac minimally invasive surgical procedures thoracoscopes cardiopulmonary bypass
healthy liver - healthy brain

Conditions: Metabolic Syndrome; Non-Alcoholic Fatty Liver Disease; NAFLD; Pre-diabetes

Summary: people with liver disease report difficulties with attention and problem-solving skills. diet plays an important role in the development of liver disease and/or pre-diabetes. the purpose of this study is to examine whether participation in a brief diet intervention (up to 3 weeks) can improve brain and liver health and function.

the importance of liver function for brain and cognitive health is undeniable. specifically, adults with chronic liver diseases such as non-alcoholic fatty liver disease (nafld), a factor of metabolic syndrome (mets), experience a range of symptoms including problems with attention, problem solving skills and executive function. importantly, diet plays a role in the development of nafld. the investigators propose to be the first to demonstrate that metabolic syndrome-related brain vulnerability, in the form of elevated free cerebral glutamate, is related to hepatic triglyceride level, through experimental manipulation of liver fat and multiorgan imaging. the investigators seek to improve liver health by altering diet content in a block randomized feeding trial. the investigators selected a low-carbohydrate (\<30 g/d) diet (locho) to reduce liver fat and a low-calorie (local) diet as a control for weight loss. the investigators hypothesize that locho diet will improve cognitive performance by improving liver health and thus, brain health. this work may provide a way to support brain function in mets and delay cognitive decline.

Eligibility criteria:
inclusion criteria: * at least 40 years of age * english speakers * show a minimum of 5% hepatic triglyceride level on liver imaging * have not taken part in a weight loss/dietary intervention within 6 months * not currently adhering to a low-carbohydrate diet (e.g., atkins, paleo) exclusion criteria: * younger than 40 years of age * have a history of neurological disease (e.g. stroke, seizure disorder) * psychiatric illness (e.g. schizophrenia, bipolar disorder) * harmful alcohol use (audit-c score \>5) * morbid obesity (bmi\>40) * mri contraindications

Keywords: neuroimaging liver low-carbohydrate diet